Tirzepatide cardiovascular safety — looking for input

A narrower follow-up, since the general answer is now clear:

What would you measure differently if you were starting again?

josh_phd_bmore said:

Lp(a) and cardiovascular risk: a nuance that matters.

josh_phd_bmore said:

...we're creating a generation dependent on cardiovascular risk...

I understand the concern, but consider this analogy: are we "creating a generation dependent on" blood pressure medication? Cholesterol medication? Thyroid medication?

Obesity is a chronic disease with biological drivers. Treating it with medication is no different from treating any other chronic condition. The "dependency" framing implies weakness or moral failure — neither of which is accurate.

If ongoing medication is what keeps someone healthy, that's successful treatment, not dependency.

josh_phd_bmore said:

Lp(a) and cardiovascular risk: a nuance that matters.

6 month update on cardiovascular risk: down 44 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

josh_phd_bmore said:

Lp(a) and cardiovascular risk: a nuance that matters.

That reframing is the part I needed. Printing the relevant bit and taking it with me.

KristenIndy said:

6 month update on cardiovascular risk: down 44 lbs, off blood pressure meds, A1C normalized.

KristenIndy said:

...cardiovascular risk is just another fad...

I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:

• Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
• Published in NEJM, JAMA, Lancet (not press releases)
• Replicated across multiple independent research groups
• Proven cardiovascular and renal benefits beyond weight loss
• Biological mechanism fully characterized at the receptor level

This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.